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Objectives: The Ser326Cys polymorphism in the human 8-oxogunaine glycosylase (hOGG1) gene with lung cancer
susceptibility had been investigated, but results were inconsistent and underpowered. The aim of this study was to
conduct a meta-analysis assessing the association of hOGG1 Ser326Cys polymorphism with risk of lung cancer.
Materials and methods: Relevant studies were identified through a search of MEDLINE, PubMed, Web of Science,
EMBASE, and Chinese Biomedical Literature database (CBM) using terms “lung cancer”, “hOGG1” or “OGG1”,
“polymorphism” or “variation” and the last search updated on May 1, 2013. In this meta-analysis, we assessed 30
published studies involving 22,475 subjects that investigated the association between the hOGG1 Ser326Cys
polymorphism and lung cancer susceptibility.
Results: Overall, the hOGG1 Ser326Cys polymorphism was not associated with lung cancer susceptibility in
different genetic models (dominant model comparison: OR = 0.133; 95% CI = 0.111–0.161; Pheterogeneity = 0.000), and
recessive model: OR = 0.543; 95% CI = 0.399–0.739; Pheterogeneity = 0.000). Similarly, in the stratified analyses by
ethnicity, significantly increased risks were found among Asians for homozygote comparison (OR = 0.850; 95%
CI = 0.732 0.986; Pheterogeneity = 0.064), and dominant model (OR = 0.160; 95% CI = 0.137–0.187; Pheterogeneity = 0.001),
and Caucasians for dominant model (OR = 1.35; 95% CI = 1.03–1.77; Pheterogeneity = 0.015), and recessive model
(OR = 1.35; 95% CI = 1.03–1.77; Pheterogeneity = 0.015). In population-based populations, marginally significant
increased risks were found in dominant model (OR = 0.143; 95% CI = 0.111 0.184; Pheterogeneity = 0.000) and recessive
model (OR = 0.429; 95% CI = 0.261–0.705; Pheterogeneity = 0.000). We also found a significant difference between
hOGG1 Ser326Cys genotype and lung cancer susceptibility in studies with hospital-based controls for homozygote
model (OR = 0.798; 95% CI = 0.649–0.982; Pheterogeneity = 0.007),dominant model (OR = 0.122; 95% CI = 0.091–0.163;
Pheterogeneity = 0.000).
Conclusion: Our data showed that the hOGG1 Ser326Cys polymorphism contributed to the risk of lung cancer.
Virtual slides: The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
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Lung cancer has become one of the most common malig-
nancies all over the world with an extremely low survival
rate is one of the leading causes to contribut to cancer
mortality [1]. A number of environmental and genetic risk
factors for lung cancer have been identified, and it is
caused primarily by tobacco smoke, as manifested by the
fact that 80% to 90% of lung cancer patients are smokers,
while “only” 10% to 15% of heavy smokers develop lung
cancer, suggesting the existence of personal risk factors of
genetic origin, which predispose a fraction of smokers to
the disease [2-5]. DNA damage may lead to carcinogenesis
through inactivation of tumor suppressor genes or activa-
tion of oncogenes [6,7], and recent studies have focused
on the association between genetic polymorphisms in dif-
ferent genes and risk of lung cancer [8-10], and they were
certified by different techniques [11].
The 8-oxoguanine lesion is one of themajor forms of
oxidative DNA damage [12,13], and it can be removed
from DNA by human 8-oxoguanine DNA N-glycosylase
1 (hOGG1) [14]. This glycosylase has been suggested as
a possible suppressor of lung carcinogenesis in OGG1-
knockout mice [15], and in a bacterial complementation
assay system the hOGG1 Cys326 allele was postulated to
reduce the activity of 8-oxoguanine lesion removal [16].
8-Oxodeoxyguanosine, the most abundant lesion gener-
ated by oxidative stress from the environment and nor-
mal cellular metabolism, is highly mutagenic resulting in
GC to TA transversion [17,18]. hOGG1 gene located on
chromosome 3 encodes a DNA glycosylase/apurinic-
apyrimidinic lyase that catalyzes the excision and
removal of 8-hydroy-2-deoxyguanine adducts [19]. An
approximately 2-fold increased risk of lung cancer asso-
ciated with the Cys/Cys or Ser/Cys genotype of hOGG1
has been observed in many different ethnicity popula-
tions [20-22]. In the past years, the hOGG1 Ser326Cys
polymorphism has attracted widespread attention. Pre-
vious epithio studies were performed to identify the as-
sociation of Ser326Cys polymorphism with lung cancer
risk [16,20-46]. However, the results remain inconclusive
and inconsistent. Therefore, a meta-analysis was per-
formed in our present study to further evaluate the asso-
ciation between hOGG1 Ser326Cys polymorphism and




A comprehensive search strategy was conducted towards
the electronic databases including MEDLINE, PubMed,
Web of Science, EMBASE, and Chinese Biomedical
Literature database (CBM) using terms “lung cancer”,
“hOGG1” or “OGG1”, “polymorphism” or “variation” and
the last search updated on May 1, 2013. Among thestudies retrieved, eligible ones were determined and their
bibliographies were evaluated for other relevant publica-
tions. Review articles and bibliographies of other relevant
studies identified were hand-searched to identify add-
itional eligible studies. Only published studies with full
text articles were included. When more than one of the
same patient population was included in several publica-
tions, only the most recent or complete study was used
in this meta-analysis.
Inclusion criteria and exclusion criteria
The following inclusion criteria were used to select lite-
ratures for the meta-analysis: (1) Only the case–control
studies were considered; (2) The paper should clearly
describe lung cancer diagnoses and the sources of cases
and controls; (3) The authors must offer the size of the
sample, OR and their 95% CI or the information that
can help infer the results in the papers (provided the
number of individuals homozygous for Ser/Ser, Cys/Cys
and heterozygous for Ser/Cys in lung cancer cases and
controls). The exclusion criteria were: (1) none-case–
control studies; (2) control population including malig-
nant tumor patients; and (3) duplicated publications.
Data extraction
Information was carefully extracted from all eligible pub-
lications independently by two authors according to the
inclusion and exclusion criteria listed above. An agree-
ment was reached by discussion between the two re-
viewers whenever there was a conflict. The following
data were collected from each study: first author’s sur-
name, year of publication, country, ethnicity, source of
controls (Population-Based and Hospital-Based popula-
tion), and numbers of cases and controls with the Ser/
Ser, Ser/Cys, and Cys/Cys genotypes, respectively. Diffe-
rent ethnicity descents were categorized as Caucasian
and Asian population. When studies included subjects
of more than one ethnicity and were able to separate,
data were extracted separately for each ethnic group.
We did not define any minimum number of patients to
include a study in our meta-analysis.
Statistical analysis
Crude odds ratios (ORs) with 95% confidence intervals
(CIs) were used to assess the strength of association bet-
ween the hOGG1 Ser326Cys polymorphism and lung
cancer risk according to the method of Woolf [47].
Homozygote model (Ser/Ser vs Cys/Cys), heterozygote
model (Ser/Ser vs Ser/Cys, Ser/Cys VS Cys/Cys), domi-
nant (Ser/Ser + Ser/Cys vs Cys/Cys), recessive model
(Ser/Ser vs Ser/Cys + Cys/Cys) and Ser-allele compared
Cys-allele model (Ser-allele vs Cys-allele) were esti-
mated, respectively. Subgroup analyses were done by
ethnicity and source of controls. Both fixed-effects
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random-effects model using the DerSimonian and Laird
method [49] were used to pool the results.
Heterogeneity assumption was checked by the Chi-
square-based Q-test [50]. A P-value greater than 0.10 for
the Q-test indicates a lack of heterogeneity among stu-
dies, so the pooled OR estimate of the each study was
calculated by the fixed-effects model. Otherwise, the
random-effects model was used. The significance of the
pooled OR was determined by the Z-test, and P < 0.05
was considered as statistically significant. One-way sensi-
tivity analyses were performed to assess the stability of
the results, namely, a single study in the meta-analysis
was deleted each time to reflect the influence of the in-
dividual data set to the pooled OR. Begg’s funnel plots
[51] and Egger’s regression method [52] were used to
assess publication bias statistically (p < 0.05 was consi-
dered representative of statistically significantly publica-
tion bias). Hardy–Weinberg equilibrium in the controlFigure 1 Flow chart illustrating the selection of studies.group was tested by the Chi-square test for goodness of
fit, and a P-value of <0.05 was considered significant. All
of the calculations were performed using STATA version
12.0 (Stata Corporation, College Station, TX).
Results
Study characteristics
Studies relevant to the searching words were retrieved
originally. The initial search algorithm retrieved 229
references. After careful review of the abstracts, 155 of
studies were excluded because they obviously did not
meet the inclusion criteria for the meta-analysis. After
this exclusion, 74 studies were left for full publication
review. After review of the complete articles, 47 studies
were excluded because of a lack of sufficient information
or methods discrepancies. A total of 30 studies involving
10,327 lung cancer cases and 12,148 controls were
ultimately analyzed (Figure 1). Table 1 presents the main
characteristics of these studies. Almost all of the cases
Table 1 Main characteristics of these studies included in this meta-analysis
First author
[Inference]
Year Country Ethnicity Control
source
Cases Controls PHWE
Ser/Ser Ser/Cys Cys/Cys Ser/Ser Ser/Cys Cys/Cys
Kohno 1998 Japan Asian PB 16 19 10 15 20 7 0.93
Le Marchand a 2002 USA Caucasian PB 78 39 9 98 53 8 0.81
Le Marchand b 2002 USA Asian PB 30 40 27 50 74 26 0.88
Lan 2004 China Asian PB 37 61 20 51 43 15 0.23
Vogel 2004 Denmark Caucasian PB 149 93 14 159 91 19 0.24
Loft 2006 Denmark Caucasian PB 144 93 14 154 88 19 0.20
Matullo 2006 Italy Caucasian PB 66 46 4 673 371 50 0.90
Sorensen 2006 Denmark Caucasian PB 254 155 22 479 284 33 0.26
Zienolddiny 2006 Italy Caucasian PB 182 100 44 194 117 75 0.01
Hatt 2008 Denmark Caucasian PB 92 58 8 93 59 12 0.54
Karahalil 2008 Turkey Caucasian PB 86 65 14 115 106 29 0.55
Okasaka 2009 Japan Asian PB 117 257 141 250 544 236 0.07
Li 2011 China Asian PB 83 208 164 60 219 164 0.33
Qian 2011 China Asian PB 100 288 193 125 291 185 0.59
Sugimura 1999 Japan Asian HB 85 115 41 63 107 27 0.08
Wikman 2000 Germany Caucasian HB 68 32 5 60 43 2 0.07
Ito 2002 Japan Asian HB 40 71 27 68 118 54 0.84
Sunaga 2002 Japan Asian HB 54 106 38 50 66 36 0.13
Park 2004 USA Caucasian HB 101 65 13 255 87 8 0.86
Hung 2005 European Caucasian HB 1401 661 93 1368 716 79 0.22
Liang 2005 China Asian HB 27 132 68 28 123 76 0.04
Wang 2005 China Asian HB 49 51 24 45 70 13 0.06
Kohno 2006 Japan Asian HB 285 544 268 123 190 81 0.63
De Ruyck 2007 Belgium Caucasian HB 74 33 3 60 46 4 0.18
Chang 2009 China Asian HB 142 518 436 154 482 361 0.74
Gao 2009 China Asian HB 27 35 24 30 49 11 0.19
Miyaishi 2009 Japan Asian HB 27 55 26 39 54 28 0.27
Liu 2010 China Asian HB 68 158 132 110 294 312 0.01
Janik 2011 Poland Caucasian HB 48 24 16 57 21 1 0.54
Kohno 2011 Japan Asian HB 115 162 100 98 164 63 0.70
a,b Two different ethnicity studies in one publication. PB Population-Based Study, HB Hospital-Based Study, PHWE P value of Hardy–Weinberg Equilibrium.
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healthy populations. There were a total of 30 studies
including 17 groups of Asians, and 13 groups of
African-Americans. Simultaneously, there were 14
population-based studies and 16 hospital-based stu-
dies. The distribution of genotypes in the controls of
all studies was in agreement with Hardy–Weinberg
equilibrium except for three studies [27,37,44].
Meta-analysis results
Table 2 lists the main results of this meta-analysis. Over-
all, significantly elevated lung cancer risk were associatedin both dominant (OR = 0.133; 95% CI = 0.111–0.161;
Pheterogeneity = 0.000, P = 0.000) (Figure 2), and recessive
model (OR = 0.543; 95% CI = 0.399–0.739; Pheterogeneity =
0.000, P = 0.000) (Figure 3) when all the eligible studies
were pooled into the meta-analysis. However, there were
no significant associations in homozygote model (OR =
0.885; 95% CI = 0.765–1.024; Pheterogeneity = 0.002, P = 0.101),
heterozygote model (OR = 0.982; 95% CI = 0.898–1.075;
Pheterogeneity = 0.023, P = 0.698 for Ser/Ser vs Ser/Cys
model; OR = 0.909; 95% CI = 0.802–1.029; Pheterogeneity =
0.006, P = 0.131 for Ser/Cys vs Cys/Cys), and also the
Ser-allele were not associated with an increased cancer
Table 2 Main results of pooled odds ratios (ORs) with confidence interval (CI) in the meta-analysis
Variables No. of studies Ser/Ser vs Cys/Cys Ser/Ser vs Ser/Cys Ser/Cys vs Cys/Cys
OR (95% CI) Ph P OR (95% CI) Ph P OR (95% CI) Ph P
Total 30 0.885(0.765 1.024) 0.002 0.101 0.982(0.898 1.075) 0.023 0.698 0.909(0.802 1.029) 0.006 0.131
Ethnicity
Asian 17 0.850(0.732 0.986) 0.064 0.032 0.973(0.860 1.100) 0.102 0.659 0.887(0.771 1.020) 0.012 0.092
Caucasian 13 0.946(0.683 1.310) 0.005 0.738 0.993(0.866 1.138) 0.041 0.915 0.970(0.734 1.281) 0.070 0.829
Source of controls
PB 14 0.993(0.810 1.216) 0.069 0.945 0.974(0.877 1.083) 0.377 0.630 0.956(0.833 1.098) 0.367 0.527
HB 16 0.798(0.649 0.982) 0.007 0.033 0.991(0.858 1.144) 0.007 0.900 0.837(0.689 1.017) 0.001 0.073
Variables No. of studies Ser/Ser + Ser/Cys vs Cys/Cys (dominant) Ser/Ser vs Ser/Cys + Cys/Cys (recessive) Ser allele vs Cys allele
OR (95% CI) Ph P OR (95% CI) Ph P OR (95% CI) Ph P
Total 30 0.133(0.111 0.161) 0.000 0.000 0.543(0.399 0.739) 0.000 0.000 0.947(0.880 1.019) 0.000 0.143
Ethnicity
Asian 17 0.160(0.137 0.187) 0.001 0.000 0.875(0.684 1.118) 0.000 0.285 0.931(0.865 1.000) 0.064 0.052
Caucasian 13 0.101(0.069 0.147) 0.000 0.000 0.300(0.198 0.454) 0.000 0.000 0.970(0.836 1.125) 0.000 0.686
Source of controls
PB 14 0.143(0.111 0.184) 0.000 0.000 0.429(0.261 0.705) 0.000 0.001 0.979(0.897 1.069) 0.087 0.644
HB 16 0.122(0.091 0.163) 0.000 0.000 0.670(0.455 0.986) 0.000 0.042 0.916(0.817 1.026) 0.000 0.131
Ph P value of heterogeneity.
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95% CI = 0.880–1.019; Pheterogeneity = 0.000, P = 0.143).
In the stratified analysis by ethnicity, significantly in-
creased risks were found among Asians for homozygote
model (OR = 0.850; 95% CI = 0.732 0.986; Pheterogeneity =
0.064, P = 0.032), dominant model (OR = 0.160; 95%
CI = 0.137–0.187; Pheterogeneity = 0.001, P = 0.000) (Table 2
and Figure 2). Simultaneously, significantly increased risks
were found among Caucasians for dominant model
(OR = 1.35; 95% CI = 1.03–1.77; Pheterogeneity = 0.015)
(Table 2 and Figure 2), and recessive model (OR = 1.35;
95% CI = 1.03–1.77; Pheterogeneity = 0.015) (Table 2 and
Figure 3). However, no significant associations were found
in both Asians and Caucasians for other genetic models
(Table 2). When stratifying this meta-analysis by control
sources, we also found a significant difference between
hOGG1 Ser326Cys genotype and lung cancer susceptibi-
lity in studies with hospital-based controls for homozygote
model (OR = 0.798; 95% CI = 0.649–0.982; Pheterogeneity =
0.007; P = 0.033), dominant model (OR = 0.122; 95% CI =
0.091–0.163; Pheterogeneity = 0.000; P = 0.000), and recessive
model (OR = 0.670; 95% CI = 0.455–0.986; Pheterogeneity =
0.000; P = 0.042) (Table 2). In population-based studies,
marginally significant increased risks were found in
dominant model (OR = 0.143; 95% CI = 0.111 0.184;
Pheterogeneity = 0.000; P = 0.000) and recessive model
(OR = 0.429; 95%CI = 0.261–0.705; Pheterogeneity = 0.000;
P = 0.001) (Table 2).Test of heterogeneity
There was significant heterogeneity for homozygote
comparison (P = 0.002), heterozygote comparison (P =
0.023 for Ser/Ser vs Ser/Cys model and P = 0.006 for
Ser/Cys vs Cys/Cys), dominant model comparison
(P = 0.000), recessive model comparison (P = 0.000)
and Ser-allele vs Cys-allele comparison (P = 0.000).
After assessing the source of heterogeneity for all
genetic model comparison by subgroup analysis on
ethnicity and control sources, the heterogeneity was
partly decreased. When we deleted these three studies
[27,37,44] for departure from HWE, the heterogeneity
was completely removed.
Sensitivity analysis
A single study involved in the meta-analysis was deleted
each time to reflect the influence of the individual data
set to the pooled ORs, and the corresponding pooled
ORs indicated that three studies were the main origin of
heterogeneity. The heterogeneity was completely re-
moved after exclusion of these studies. Although these
studies did not follow HWE, the corresponding pooled
ORs were not materially altered with or without inclu-
ding them almost in all genetic models. Similarly, no
other single study influenced the pooled OR qualita-
tively, as indicated by sensitivity analysis, suggesting
that the results of this meta-analysis are stable (Data
were not show in this paper).
Figure 2 Forest plot of the odds ratios (ORs) and 95% confidence intervals (CIs) of studies of the association between the lung cancer
risk and the hOGG1 Ser326Cys polymorphism (Dominant model comparison).
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Begg’s funnel plot and Egger’s test were performed to as-
sess the publication bias of the literature. The shapes of
the funnel plots did not reveal any evidence of obvious
asymmetry in all comparison models (Figure 4). Further-
more, Egger’s test was used to provide statistical evi-
dence for funnel plot symmetry. The results still did not
suggest any evidence of publication bias.
Discussion
It is well recognized that there is a range of individual
susceptibility to the same kind of cancer even with identi-
cal environmental exposure. Host factors, including poly-
morphisms of genes involved in carcinogenesis, may have
accounted for this difference. Therefore, genetic suscep-
tibility to cancer has been a research focus in scientific
community. Among the common single nucleotide poly-
morphisms (SNPs) of the hOGG1 gene, one located in
exon 7, resulting in an amino acid substitution of serine
(Ser) with cysteine (Cys) at codon 326 (Ser326Cys,rs1052133), has been demonstrated to affect hOGG1
function [53]. The protein resulting from this substitution
exhibits reduced DNA repair activity [53], and this SNP
has been reported to be associated with the risk of many
types of cancer [54]. Epidemiological studies of the OGG1
Ser326Cys polymorphism in relation to cancer have
yielded mixed results with a weak association between the
OGG1 Ser326Cys genotype and the risk of lung cancer.
Wikman et al. carried out a case–control study which sug-
gested that the hOGG1 polymorphisms were probably not
major contributors to individual lung cancer susceptibility
in Caucasians [33]. Hung et al. also observed that there
were no such associations between them [36]. The same
results were found in other studies [23]. Sugimura et al.
found that the Ser326Cys polymorphism was not asso-
ciated with an increased risk of lung cancer in any sub-
types; however, when homozygous Cys326Cys were
compared with other genotypes in combination, an in-
creased risk was observed for the squamous cell carci-
noma and nonadenocarcinoma after adjustment for age
Figure 3 Forest plot of the odds ratios (ORs) and 95% confidence intervals (CIs) of studies of the association between the lung cancer
risk and the hOGG1 Ser326Cys polymorphism (Recessive model comparison).
Figure 4 Begg funnel plot analysis to detect potential publication bias.
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http://www.diagnosticpathology.org/content/8/1/144and smoking [32]. Ito et al. found no any effects of the
OGG1 Ser326Cys polymorphism on the development of
either adenocarcinomas or small cell carcinoma [34]. De
Ruyck et al. found a reduced cancer risk associated with
the OGG1 Ser326Cys polymorphism [40]. Individual
studies on the relationships between SNPs of genes and
cancer risk always yield inconsistent and controversial re-
sults partly because of a rather small sample size and low
precision. Meta-analysis could solve the problem caused
by the low statistical power of single studies and enable
drawing of a more robust conclusion. Since there have
been contradictory findings so far, we conducted a meta-
analysis of 10,327 lung cancer cases and 12,148 controls
to investigate its association with lung cancer risk.
The meta-analysis of Hung et al. showed that the sum-
mary OR was 1.37 (95% CI = 1.02–1.82) for the Cys/Cys
genotype in various ethnic populations combined [55].
Li et al. performed another meta-analysis showed that
individuals carrying the Cys/Cys genotype did not have
significantly increased risk of lung cancer in all popula-
tions combined but, in the stratified analysis by eth-
nicity, a significantly increased risk was found among
Asians (OR = 1.18, 95% CI = 1.01–1.38) [56]. Our work,
including 22,475 subjects from 30 published case–control
studies, explored the association between a potentially
functional polymorphism, hOGG1 Ser326Cys and lung
cancer susceptibility. We found that the variant genotypes
of the hOGG1 were associated with a significant increased
overall risk of lung cancer. When stratified according to
ethnicity, Asians with the Ser/Ser showed a higher risk of
lung cancer compared with those with the Cys/Cys geno-
type. However, Caucasians did not show the same risk.
Ethnic difference in the association between lung cancer
risk and the hOGG1 Ser326Cys polymorphism was
suggested. Large studies including different ethnic groups
with a careful matching between cases and controls
should be considered in future association studies to
confirm results from the meta-analyses.
Heterogeneity is a potential problem when interpreting
the results of all meta-analyses. As looked through our
study carefully, we found that the three studies [27,37,45]
were noted to be a major source of heterogeneity. The
reason may be that the study was only among non-
smokers, and the controls were found to be out of HWE.
Although this study was a major source of heterogeneity,
the corresponding pooled ORs were not materially altered
with or without including it almost in all genetic models,
suggesting that the results of this meta-analysis are stable.
Some limitations of this meta-analysis should be ad-
dressed. Firstly, lung cancer is a multi-factorial disease
that results from complex interactions between many
genetic and environmental factors. This means that
there will not be single gene or single environmental fac-
tor that has large effects on lung cancer susceptibility.Our results were based on unadjusted estimates, while a
more precise analysis should be conducted if individual
data were available, which would allow for the adjust-
ment by other covariates including age, sex, family his-
tory, environmental factors and lifestyle. Secondly, in the
subgroup analyses by ethnicity, control sources, the
number of subjects was relatively small, not having
enough statistical power to explore the real association.
Thirdly, the controls were not uniformly defined. Al-
though most of the controls were selected mainly from
healthy populations, some had respiratory disease. There-
fore, non-differential misclassification bias was possible
because these studies may have included the control
groups who had different risks of developing lung cancer.
Conclusion
Despite some limitations listed above, this work suggests
that the hOGG1 Ser326Cys variant is a risk factor for
developing lung cancer. Additionally, we found that this
phenomenon was more prominent in subgroups such as
in Asians. However, it is necessary to conduct large studies
using standardized unbiased methods, homogeneous lung
cancer patients and well matched controls, with the
assessors blinded to the data. Moreover, gene–gene and
gene–environment interactions should also be considered
in future analysis. Such studies taking these factors into
account may eventually lead to our better, comprehensive
understanding of the association between the hOGG1
Ser326Cys polymorphism and lung cancer risk.
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